–Presentations highlight company’s expertise seamlessly integrating
human biology, data science and modern chemistry to advance a pipeline
of investigational breakthrough precision oncology medicines–
CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a U.S.-based precision medicine research &
development subsidiary of Eisai Co., Ltd., today announced multiple
presentations at the upcoming American Association for Cancer Research
(AACR) Annual Meeting, being held March 29 through April 3, 2019 at the
Georgia World Congress Center in Atlanta, GA.
Leveraging its integrated data science, human biology and precision
chemistry discovery engine, H3 is advancing a pipeline of highly
targeted, investigational breakthrough medicines to address critical
unmet needs in the treatment of hematologic and solid tumor cancers. The
company currently has three precision medicine therapeutic programs in
clinical study with several additional research programs advancing
toward the development stage.
H3’s presentations at this year’s AACR Annual Meeting showcase the
company’s breadth of expertise in oncology research and the molecular
insights enabled by its unique discovery engine.
The schedule for H3’s presentations is as follows (in chronological
order):
Oral Presentation/Education Session:
Title: Targeting the spliceosome; perspectives from structural
biology
Session: Chemistry to the Clinic: Part 2: Novel
Chemical Tools and Leads for Unprecedented Targets
Date and
Time: Saturday, March 30, 2019; 10:15 a.m. – 12:15 p.m. EDT
Location:
Room A311-312
Presenter: Nicholas Larsen, Ph.D.,
Director, H3 Biomedicine
Poster Presentations:
Abstract Number: 281
Title: Sensitivity to
splicing modulation of BCL2 family genes reveals cancer therapeutic
strategies for splicing modulators
Session: Combination
Approaches to Novel Therapies
Date and Time: Sunday March
31, 2019; 1:00 p.m. – 5:00 p.m. EDT
Location: Exhibit Hall
B; Poster Section 12; Poster Board Number 2
Abstract Number: 498
Title: Integrating bulk and
spatial profiling technologies for the discovery of RNA and protein
biomarkers in muscle invasive bladder cancer
Session: Imaging
the Tumor Microenvironment
Date and Time: Sunday, March 31,
2019; 1:00 p.m. – 5:00 p.m. EDT
Location: Exhibit Hall B;
Poster Section 20; Poster Board Number 11
Abstract Number: 2467
Title: Heme-CMap:
Generation and characterization of ~20K L1000 profiles across 11
hematologic malignant lines
Session: Databases and
Computational Tools for Cancer Discovery
Date and Time: Monday
April 1, 2019; 1:00 p.m. – 5:00 p.m. EDT
Location: Exhibit
Hall B; Poster Section 31; Poster Board Number 7
** In
collaboration with the Broad Institute
About H3 Biomedicine
H3 Biomedicine, Inc. is a Cambridge, Massachusetts-based
biopharmaceutical company specializing in the discovery and development
of novel precision oncology treatments using its integrated data
science, human biology and precision chemistry discovery engine with the
goal of improving the lives of patients. The company was established in
December 2010 as a subsidiary of Eisai’s U.S. pharmaceutical operation,
Eisai Inc. H3 Biomedicine focuses on sustained long-term delivery of its
pipeline, collaborating with Eisai Co., Ltd., who provides essential
research funding and access to the capabilities and resources of a
global pharmaceutical company. For more information, please visit www.h3biomedicine.com.
Contacts
Media Inquiries
Liz Melone
elizabeth_melone@h3biomedicine.com
617-256-6622